Elevated MCT2 (SLC16A7) levels were associated with increased expression of interleukin-1β (IL-1β) and lipocalin-2 (LCN2), both of which are linked to tumour progression and adverse outcomes [105]. This evidence concerns the gene SLC16A7 and neoplasm.